Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of SKB518 in lung cancer
CTR20252228Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SKB518 in bronchial carcinoma, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Primary endpoints: Incidence and severity of adverse events, Objective response rate in Cohorts A and C and 1 more. Started Aug 2025; status: active.
02
Drugs
SKB518
03
Conditions
bronchial carcinomasmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252228.